Indolent lymphoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bortezomib and Rituximab (VR) Variant #06 | — | R 64 235 | 35d | ~12.8 mo | — | ~12 | ~R 770 814 PFS proxy · indirect | 1 |
R-TBI/Cy Variant #01 | — | R 24 768 | — | — | — | — | — | — |
R-BEAM Variant #01 Partial | — | R 22 812 | — | — | — | — | — | — |
3 of 3 regimens shown